The latest price target for Treace Medical Concepts (NASDAQ:TMCI) was reported by Truist Securities on December 18, 2024. The analyst firm set a price target for $8.40 expecting TMCI to rise to within 12 months (a possible 20.68% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Treace Medical Concepts (NASDAQ:TMCI) was provided by Truist Securities, and Treace Medical Concepts maintained their hold rating.

The last upgrade for Treace Medical Concepts Inc happened on January 7, 2022 when Morgan Stanley raised their price target to $30. Morgan Stanley previously had an equal-weight for Treace Medical Concepts Inc.

The last downgrade for Treace Medical Concepts Inc happened on May 16, 2024 when UBS changed their price target from $16 to $6.5 for Treace Medical Concepts Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Treace Medical Concepts, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Treace Medical Concepts was filed on December 18, 2024 so you should expect the next rating to be made available sometime around December 18, 2025.

While ratings are subjective and will change, the latest Treace Medical Concepts (TMCI) rating was a maintained with a price target of $7.00 to $8.40. The current price Treace Medical Concepts (TMCI) is trading at is $6.96, which is out of the analyst’s predicted range.